25 XP   0   0   10

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Buy, Hold or Sell?

Let's analyse Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd together

PenkeI guess you are interested in Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

I send you an email if I find something interesting about Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Quick analysis of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (30 sec.)










What can you expect buying and holding a share of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd? (30 sec.)

How much money do you get?

How much money do you get?
HK$0.04
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
HK$2.37
Expected worth in 1 year
HK$2.77
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
HK$0.69
Return On Investment
32.2%

For what price can you sell your share?

Current Price per Share
HK$2.15
Expected price per share
HK$2.08 - HK$2.24
How sure are you?
50%

1. Valuation of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (5 min.)




Live pricePrice per Share (EOD)

HK$2.15

Intrinsic Value Per Share

HK$-1.57 - HK$2.19

Total Value Per Share

HK$0.80 - HK$4.56

2. Growth of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (5 min.)




Is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$312.1m$303.2m$8.8m2.8%

How much money is Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd making?

Current yearPrevious yearGrowGrow %
Making money$19m$29.4m-$10.4m-54.6%
Net Profit Margin13.4%18.7%--

How much money comes from the company's main activities?

3. Financial Health of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (5 min.)




What can you expect buying and holding a share of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd? (5 min.)

Welcome investor! Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's management wants to use your money to grow the business. In return you get a share of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

What can you expect buying and holding a share of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd?

First you should know what it really means to hold a share of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd. And how you can make/lose money.

Speculation

The Price per Share of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is HK$2.15. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is HK$2.37. Based on the TTM, the Book Value Change Per Share is HK$0.10 per quarter. Based on the YOY, the Book Value Change Per Share is HK$0.19 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is HK$0.07 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 HK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per ShareHK$% of Price per Share
Usd Eps0.020.9%0.020.9%0.031.3%0.021.1%0.020.9%
Usd Book Value Change Per Share0.010.6%0.010.6%0.021.1%0.031.6%0.031.2%
Usd Dividend Per Share0.010.4%0.010.4%0.010.3%0.010.4%0.010.3%
Usd Total Gains Per Share0.021.0%0.021.0%0.031.5%0.042.0%0.031.5%
Usd Price Per Share0.44-0.44-0.49-0.50-0.66-
Price to Earnings Ratio23.91-23.91-17.40-22.06-36.22-
Price-to-Total Gains Ratio20.04-20.04-15.68-88.68-66.10-
Price to Book Ratio1.46-1.46-1.69-2.49-4.95-
Price-to-Total Gains Ratio20.04-20.04-15.68-88.68-66.10-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.27477
Number of shares3639
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share0.010.03
Usd Total Gains Per Share0.020.04
Gains per Quarter (3639 shares)80.51152.84
Gains per Year (3639 shares)322.06611.36
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1139183312118494601
22783666342359881212
341754995635314811823
4556732127847019752434
5695915160058824693045
68341099192270529633656
79731282224482334574267
811121465256694039504878
9125116482888105844445489
10139018313210117649386100

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%14.05.02.066.7%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%4.01.00.080.0%9.01.00.090.0%15.06.00.071.4%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%11.00.010.052.4%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%16.05.00.076.2%

Fundamentals of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in phase I clinical trials for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

Fundamental data was last updated by Penke on 2024-03-25 06:50:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is fair priced.

1.1. Profitability of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 13.4% means that $0.13 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

  • The MRQ is 13.4%. The company is making a huge profit. +2
  • The TTM is 13.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ13.4%TTM13.4%0.0%
TTM13.4%YOY18.7%-5.3%
TTM13.4%5Y18.9%-5.5%
5Y18.9%10Y20.0%-1.1%
1.1.2. Return on Assets

Shows how efficient Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 4.6% Return on Assets means that Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd generated $0.05 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

  • The MRQ is 4.6%. Using its assets, the company is less efficient in making profit.
  • The TTM is 4.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.6%TTM4.6%0.0%
TTM4.6%YOY7.7%-3.0%
TTM4.6%5Y8.8%-4.1%
5Y8.8%10Y10.1%-1.4%
1.1.3. Return on Equity

Shows how efficient Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 6.1% Return on Equity means Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd generated $0.06 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

  • The MRQ is 6.1%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 6.1%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ6.1%TTM6.1%0.0%
TTM6.1%YOY9.7%-3.6%
TTM6.1%5Y12.9%-6.8%
5Y12.9%10Y14.1%-1.3%

1.2. Operating Efficiency of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is operating .

  • Measures how much profit Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 12.1% means the company generated $0.12  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

  • The MRQ is 12.1%. The company is operating less efficient.
  • The TTM is 12.1%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ12.1%TTM12.1%0.0%
TTM12.1%YOY14.3%-2.2%
TTM12.1%5Y17.7%-5.7%
5Y17.7%10Y19.8%-2.1%
1.2.2. Operating Ratio

Measures how efficient Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 0.96 means that the operating costs are $0.96 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

  • The MRQ is 0.964. The company is less efficient in keeping operating costs low.
  • The TTM is 0.964. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.964TTM0.9640.000
TTM0.964YOY0.906+0.058
TTM0.9645Y0.864+0.100
5Y0.86410Y0.822+0.042

1.3. Liquidity of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.07 means the company has $3.07 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

  • The MRQ is 3.073. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.073. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.073TTM3.0730.000
TTM3.073YOY3.650-0.577
TTM3.0735Y3.139-0.066
5Y3.13910Y3.185-0.046
1.3.2. Quick Ratio

Measures if Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 2.76 means the company can pay off $2.76 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

  • The MRQ is 2.756. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.756. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.756TTM2.7560.000
TTM2.756YOY3.338-0.582
TTM2.7565Y2.951-0.195
5Y2.95110Y2.402+0.548

1.4. Solvency of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.24 means that Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd assets are financed with 24.2% credit (debt) and the remaining percentage (100% - 24.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

  • The MRQ is 0.242. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.242. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.242TTM0.2420.000
TTM0.242YOY0.212+0.030
TTM0.2425Y0.275-0.033
5Y0.27510Y0.249+0.026
1.4.2. Debt to Equity Ratio

Measures if Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 31.9% means that company has $0.32 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

  • The MRQ is 0.319. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.319. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.319TTM0.3190.000
TTM0.319YOY0.268+0.050
TTM0.3195Y0.401-0.082
5Y0.40110Y0.351+0.050

2. Market Valuation of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd generates.

  • Above 15 is considered overpriced but always compare Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 23.91 means the investor is paying $23.91 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

  • The EOD is 14.816. Based on the earnings, the company is underpriced. +1
  • The MRQ is 23.912. Based on the earnings, the company is fair priced.
  • The TTM is 23.912. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD14.816MRQ23.912-9.096
MRQ23.912TTM23.9120.000
TTM23.912YOY17.398+6.514
TTM23.9125Y22.064+1.847
5Y22.06410Y36.219-14.155
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

  • The EOD is 26.223. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 42.324. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 42.324. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD26.223MRQ42.324-16.100
MRQ42.324TTM42.3240.000
TTM42.324YOY24.941+17.382
TTM42.3245Y32.190+10.133
5Y32.19010Y41.089-8.898
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd:

  • The EOD is 0.906. Based on the equity, the company is cheap. +2
  • The MRQ is 1.462. Based on the equity, the company is underpriced. +1
  • The TTM is 1.462. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.906MRQ1.462-0.556
MRQ1.462TTM1.4620.000
TTM1.462YOY1.692-0.230
TTM1.4625Y2.487-1.025
5Y2.48710Y4.945-2.458
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0980.0980%0.191-49%0.265-63%0.198-50%
Book Value Per Share--2.3742.3740%2.275+4%1.798+32%1.346+76%
Current Ratio--3.0733.0730%3.650-16%3.139-2%3.185-4%
Debt To Asset Ratio--0.2420.2420%0.212+14%0.275-12%0.249-3%
Debt To Equity Ratio--0.3190.3190%0.268+19%0.401-21%0.351-9%
Dividend Per Share--0.0750.0750%0.054+38%0.063+18%0.057+32%
Eps--0.1450.1450%0.221-34%0.187-22%0.158-8%
Free Cash Flow Per Share--0.0820.0820%0.154-47%0.148-44%0.098-17%
Free Cash Flow To Equity Per Share--0.0940.0940%0.049+91%0.223-58%0.152-38%
Gross Profit Margin--1.0001.0000%1.0000%-0.351+135%-0.990+199%
Intrinsic Value_10Y_max--2.185--------
Intrinsic Value_10Y_min---1.572--------
Intrinsic Value_1Y_max--0.163--------
Intrinsic Value_1Y_min--0.034--------
Intrinsic Value_3Y_max--0.533--------
Intrinsic Value_3Y_min---0.063--------
Intrinsic Value_5Y_max--0.954--------
Intrinsic Value_5Y_min---0.340--------
Market Cap700900000.000-409%3570630000.0003570630000.0000%4015550000.000-11%3865448000.000-8%4865594592.000-27%
Net Profit Margin--0.1340.1340%0.187-28%0.189-29%0.200-33%
Operating Margin--0.1210.1210%0.143-15%0.177-32%0.198-39%
Operating Ratio--0.9640.9640%0.906+6%0.864+12%0.822+17%
Pb Ratio0.906-61%1.4621.4620%1.692-14%2.487-41%4.945-70%
Pe Ratio14.816-61%23.91223.9120%17.398+37%22.064+8%36.219-34%
Price Per Share2.150-61%3.4703.4700%3.850-10%3.908-11%5.171-33%
Price To Free Cash Flow Ratio26.223-61%42.32442.3240%24.941+70%32.190+31%41.089+3%
Price To Total Gains Ratio12.419-61%20.04320.0430%15.684+28%88.680-77%66.104-70%
Quick Ratio--2.7562.7560%3.338-17%2.951-7%2.402+15%
Return On Assets--0.0460.0460%0.077-40%0.088-47%0.101-54%
Return On Equity--0.0610.0610%0.097-37%0.129-53%0.141-57%
Total Gains Per Share--0.1730.1730%0.245-29%0.329-47%0.254-32%
Usd Book Value--312140036.524312140036.5240%303267711.871+3%231915494.189+35%168145419.120+86%
Usd Book Value Change Per Share--0.0130.0130%0.024-49%0.034-63%0.025-50%
Usd Book Value Per Share--0.3030.3030%0.291+4%0.230+32%0.172+76%
Usd Dividend Per Share--0.0100.0100%0.007+38%0.008+18%0.007+32%
Usd Eps--0.0190.0190%0.028-34%0.024-22%0.020-8%
Usd Free Cash Flow--10781869.70810781869.7080%20575666.361-48%18319249.139-41%12030436.086-10%
Usd Free Cash Flow Per Share--0.0100.0100%0.020-47%0.019-44%0.013-17%
Usd Free Cash Flow To Equity Per Share--0.0120.0120%0.006+91%0.029-58%0.019-38%
Usd Market Cap89575020.000-409%456326514.000456326514.0000%513187290.000-11%494004254.400-8%621822988.858-27%
Usd Price Per Share0.275-61%0.4430.4430%0.492-10%0.499-11%0.661-33%
Usd Profit--19083947.39219083947.3920%29497178.294-35%24734854.081-23%19934703.099-4%
Usd Revenue--142601548.434142601548.4340%157696611.161-10%132069012.474+8%101794868.978+40%
Usd Total Gains Per Share--0.0220.0220%0.031-29%0.042-47%0.033-32%
 EOD+4 -4MRQTTM+0 -0YOY+10 -255Y+11 -2510Y+13 -23

3.2. Fundamental Score

Let's check the fundamental score of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1514.816
Price to Book Ratio (EOD)Between0-10.906
Net Profit Margin (MRQ)Greater than00.134
Operating Margin (MRQ)Greater than00.121
Quick Ratio (MRQ)Greater than12.756
Current Ratio (MRQ)Greater than13.073
Debt to Asset Ratio (MRQ)Less than10.242
Debt to Equity Ratio (MRQ)Less than10.319
Return on Equity (MRQ)Greater than0.150.061
Return on Assets (MRQ)Greater than0.050.046
Total8/10 (80.0%)

3.3. Technical Score

Let's check the technical score of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.120
Total0/1 (0.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Tax Provision  3,22124,54327,764-14,30113,463-9,6323,831-9,218-5,387
Income Tax Expense  14,39613,36827,764-14,30113,463-9,6323,831-9,218-5,387



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets2,976,007
Total Liabilities718,905
Total Stockholder Equity2,257,102
 As reported
Total Liabilities 718,905
Total Stockholder Equity+ 2,257,102
Total Assets = 2,976,007

Assets

Total Assets2,976,007
Total Current Assets2,069,189
Long-term Assets906,818
Total Current Assets
Cash And Cash Equivalents 1,289,303
Short-term Investments 30,000
Net Receivables 506,384
Inventory 40,527
Other Current Assets 55,365
Total Current Assets  (as reported)2,069,189
Total Current Assets  (calculated)1,921,578
+/- 147,611
Long-term Assets
Property Plant Equipment 409,135
Intangible Assets 97,147
Other Assets 186,615
Long-term Assets  (as reported)906,818
Long-term Assets  (calculated)692,897
+/- 213,921

Liabilities & Shareholders' Equity

Total Current Liabilities673,344
Long-term Liabilities49,642
Total Stockholder Equity2,257,102
Total Current Liabilities
Short-term Debt 101,000
Short Long Term Debt 101,000
Accounts payable 7,431
Other Current Liabilities 528,935
Total Current Liabilities  (as reported)673,344
Total Current Liabilities  (calculated)738,366
+/- 65,022
Long-term Liabilities
Long term Debt Total 15,599
Capital Lease Obligations 23,815
Other Liabilities 34,043
Long-term Liabilities  (as reported)49,642
Long-term Liabilities  (calculated)73,457
+/- 23,815
Total Stockholder Equity
Common Stock102,900
Retained Earnings 934,394
Capital Surplus 1,225,009
Other Stockholders Equity -5,201
Total Stockholder Equity (as reported)2,257,102
Total Stockholder Equity (calculated)2,257,102
+/-0
Other
Capital Stock102,900
Cash and Short Term Investments 1,319,303
Common Stock Shares Outstanding 1,029,000
Liabilities and Stockholders Equity 2,976,007
Net Invested Capital 2,358,102
Net Tangible Assets 2,194,781
Net Working Capital 1,395,845
Property Plant and Equipment Gross 758,743



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-31
> Total Assets 
216,389
195,032
169,063
142,905
145,017
130,377
158,452
298,831
304,154
358,881
537,296
749,216
824,481
1,020,265
1,120,753
1,145,134
1,459,363
1,564,825
2,500,701
2,781,172
2,976,007
2,976,0072,781,1722,500,7011,564,8251,459,3631,145,1341,120,7531,020,265824,481749,216537,296358,881304,154298,831158,452130,377145,017142,905169,063195,032216,389
   > Total Current Assets 
0
0
0
62,128
60,242
51,725
73,140
144,386
179,572
203,824
265,281
429,711
479,455
629,348
708,049
707,906
1,020,147
1,138,239
2,026,574
1,927,946
2,069,189
2,069,1891,927,9462,026,5741,138,2391,020,147707,906708,049629,348479,455429,711265,281203,824179,572144,38673,14051,72560,24262,128000
       Cash And Cash Equivalents 
137,841
93,368
64,924
49,755
44,180
26,280
49,351
86,898
90,305
110,069
158,267
324,927
356,097
445,997
511,284
468,144
588,221
576,799
1,396,890
1,208,856
1,289,303
1,289,3031,208,8561,396,890576,799588,221468,144511,284445,997356,097324,927158,267110,06990,30586,89849,35126,28044,18049,75564,92493,368137,841
       Short-term Investments 
5,903
12,452
14,214
475
38
10,000
0
0
143
11
2,682
157
198
391
1,322
2,506
2,633
0
0
0
30,000
30,0000002,6332,5061,3223911981572,682111430010,0003847514,21412,4525,903
       Net Receivables 
6,309
6,144
4,281
3,693
8,097
6,791
11,616
27,957
50,376
63,150
93,237
76,246
101,514
92,522
133,700
181,217
373,550
511,395
586,004
554,359
506,384
506,384554,359586,004511,395373,550181,217133,70092,522101,51476,24693,23763,15050,37627,95711,6166,7918,0973,6934,2816,1446,309
       Other Current Assets 
425
0
0
0
0
0
0
14,906
23,013
11,871
4,152
12,813
7,663
3,934
38,080
16,372
26,337
18,176
7,670
9,775
55,365
55,3659,7757,67018,17626,33716,37238,0803,9347,66312,8134,15211,87123,01314,906000000425
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
412,704
437,228
439,216
426,585
474,127
853,226
906,818
906,818853,226474,127426,585439,216437,228412,70400000000000000
       Property Plant Equipment 
42,995
48,820
43,366
51,565
56,051
55,879
60,695
74,334
83,591
111,968
221,263
264,732
285,740
297,001
304,233
314,638
279,713
262,480
255,737
321,567
409,135
409,135321,567255,737262,480279,713314,638304,233297,001285,740264,732221,263111,96883,59174,33460,69555,87956,05151,56543,36648,82042,995
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
8,937
8,937
4,937
0
0
0
0
0
000004,9378,9378,9370000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,775
24,000
28,079
0
0
0
00028,07924,00013,775000000000000000
       Intangible Assets 
4,766
8,385
6,386
12,658
13,710
1,011
246
110
95
77
1,645
2,099
2,867
10,373
9,736
13,927
11,989
75,431
86,854
116,473
97,147
97,147116,47386,85475,43111,98913,9279,73610,3732,8672,0991,64577951102461,01113,71012,6586,3868,3854,766
       Long-term Assets Other 
0
0
0
21,371
20,604
0
2,442
0
0
0
4,796
2,954
3,011
1,267
1,394
4,708
4,436
2,273
0
0
57,624
57,624002,2734,4364,7081,3941,2673,0112,9544,7960002,442020,60421,371000
> Total Liabilities 
22,140
14,521
14,980
19,178
43,320
59,336
82,569
130,463
135,449
157,814
277,183
183,291
148,062
254,425
247,699
252,652
466,079
631,676
492,211
588,226
718,905
718,905588,226492,211631,676466,079252,652247,699254,425148,062183,291277,183157,814135,449130,46382,56959,33643,32019,17814,98014,52122,140
   > Total Current Liabilities 
22,140
14,521
14,980
19,178
12,320
18,336
51,569
72,015
118,789
88,299
223,111
122,644
121,108
235,048
231,602
239,329
454,720
571,350
427,926
528,196
673,344
673,344528,196427,926571,350454,720239,329231,602235,048121,108122,644223,11188,299118,78972,01551,56918,33612,32019,17814,98014,52122,140
       Short-term Debt 
0
0
0
0
0
1,650
21,650
20,320
56,320
28,310
86,498
15,000
25,000
125,000
120,000
140,000
150,000
148,943
0
0
101,000
101,00000148,943150,000140,000120,000125,00025,00015,00086,49828,31056,32020,32021,6501,65000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
40,000
25,000
125,000
120,000
140,000
150,000
148,943
0
0
101,000
101,00000148,943150,000140,000120,000125,00025,00040,00000000000000
       Accounts payable 
1,631
1,556
3,060
2,144
602
1,117
1,177
1,342
1,145
5,357
43,827
8,843
5,838
7,965
8,088
9,211
4,777
6,828
5,268
8,166
7,431
7,4318,1665,2686,8284,7779,2118,0887,9655,8388,84343,8275,3571,1451,3421,1771,1176022,1443,0601,5561,631
       Other Current Liabilities 
20,509
11,315
10,270
15,384
10,068
15,569
28,742
50,353
61,324
54,632
92,786
98,801
90,270
102,083
49,104
35,953
94,953
90,857
381,100
457,571
528,935
528,935457,571381,10090,85794,95335,95349,104102,08390,27098,80192,78654,63261,32450,35328,74215,56910,06815,38410,27011,31520,509
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,097
13,323
11,359
60,327
64,285
63,386
49,642
49,64263,38664,28560,32711,35913,32316,09700000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,122
13,597
22,588
15,599
15,59922,58813,5972,12200000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
14,118
0
19,515
14,072
35,647
26,954
19,377
16,097
13,323
65,689
58,205
50,688
40,798
34,043
34,04340,79850,68858,20565,68913,32316,09719,37726,95435,64714,07219,515014,1180000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
9,997
17,131
36,393
52,503
50,073
12,294
14,971
32,525
36,116
43,087
43,08736,11632,52514,97112,29450,07352,50336,39317,1319,99700000000000
> Total Stockholder Equity
192,897
174,550
149,649
120,564
99,608
70,058
73,587
135,689
139,243
170,062
223,228
532,717
650,975
732,630
843,554
872,390
943,218
931,525
2,010,931
2,192,946
2,257,102
2,257,1022,192,9462,010,931931,525943,218872,390843,554732,630650,975532,717223,228170,062139,243135,68973,58770,05899,608120,564149,649174,550192,897
   Common Stock
71,000
71,000
71,000
71,000
71,000
71,000
71,000
71,000
71,000
71,000
71,000
92,300
92,300
92,300
92,300
92,300
92,300
92,300
104,300
104,300
102,900
102,900104,300104,30092,30092,30092,30092,30092,30092,30092,30071,00071,00071,00071,00071,00071,00071,00071,00071,00071,00071,000
   Retained Earnings 
4,054
0
0
0
0
-118,785
-142,187
0
0
0
-65,431
12,038
119,455
187,439
292,905
322,042
445,334
569,229
655,131
868,427
934,394
934,394868,427655,131569,229445,334322,042292,905187,439119,45512,038-65,431000-142,187-118,78500004,054
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
412,293
237,796
1,200,120
1,265,094
1,225,009
1,225,0091,265,0941,200,120237,796412,2930000000000000000
   Treasury Stock0-40,8240000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
412,211
412,211
412,293
412,199
411,898
-14,006
-13,950
-771
-4,051
-5,201
-5,201-4,051-771-13,950-14,006411,898412,199412,293412,211412,21100000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue1,022,855
Cost of Revenue-83,958
Gross Profit938,896938,896
 
Operating Income (+$)
Gross Profit938,896
Operating Expense-834,893
Operating Income187,962104,003
 
Operating Expense (+$)
Research Development223,499
Selling General Administrative375,132
Selling And Marketing Expenses-
Operating Expense834,893598,631
 
Net Interest Income (+$)
Interest Income11,172
Interest Expense-1,202
Other Finance Cost-3,645
Net Interest Income13,615
 
Pretax Income (+$)
Operating Income187,962
Net Interest Income13,615
Other Non-Operating Income Expenses-
Income Before Tax (EBT)186,233187,962
EBIT - interestExpense = -1,202
191,065
192,267
Interest Expense1,202
Earnings Before Interest and Taxes (EBIT)-187,435
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax186,233
Tax Provision--4,111
Net Income From Continuing Ops190,344190,344
Net Income191,065
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--13,615
 

Technical Analysis of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd. The general trend of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.24 < 2.24 < 2.24.

The bearish price targets are: 2.08.

Tweet this
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd. The current adx is .

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) ChartShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Stochastic Oscillator ChartShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) ChartShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) ChartShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Williams %R ChartShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Average True Range (ATR) ChartShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) ChartShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Money Flow Index (MFI) ChartShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-16STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-17STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-27SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-01CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-15MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-12-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-12CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose2.120
Total0/1 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd with someone you think should read this too:
  • Are you bullish or bearish on Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

I send you an email if I find something interesting about Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd.

Receive notifications about Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd in your mailbox!